A new era in Alzheimer's R&D: A dual approach - Bristol Myers Squibb
WEBSep 18, 2024 — Bristol Myers Squibb is exploring novel ways to treat the symptoms of psychosis in Alzheimer’s disease by selectively stimulating muscarinic receptors, an approach currently under investigation in late-stage clinical trials.
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY - Yahoo Finance
WEBJul 11, 2023 — Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.
BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal
WEBJul 11, 2023 — Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development.
With Alzheimer's drugs in focus, Bristol Myers rejoins the hunt
WEBJun 24, 2021 — Bristol Myers Squibb has agreed to pay $80 million for exclusive rights to an experimental drug for Alzheimer's disease developed by Prothena, a biotechnology company whose research focuses on dysfunctional proteins.
BMS re-joins Alzheimer's push, paying $80m for Prothena
WEBJun 24, 2021 — Just a few days after Biogen abandoned its tau-targeting Alzheimer's disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to...
How a BMS schizophrenia candidate might work in Alzheimer's
WEBJun 2, 2022 — Now, scientists at Yale University found that an experimental drug originally developed by Bristol Myers Squibb for schizophrenia repair that damage in mice. The drug, coded BMS-984923,...
Bristol Myers’ neuroscience research head explains the big …
WEBOct 27, 2023 — Like many large pharmaceutical companies, Bristol Myers Squibb hasn’t made brain drugs a top priority over the last decade. As a field, neuroscience represents a major opportunity for drugmakers. Alzheimer’s disease affects millions of people in the U.S. alone, and puts an enormous strain on the healthcare system.
Bristol Myers Squibb Strengthens Neuroscience Portfolio with ...
WEBDec 22, 2023 — With Bristol Myers Squibb’s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be well-positioned to reach those living with schizophrenia and Alzheimer’s disease psychosis.
Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau
WEBJun 24, 2021 — PRX005 is an investigational best-in-class anti-tau antibody targeting the microtubule binding region of tau for the treatment of Alzheimer’s disease; Phase 1 study has initiated
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb…
WEBJun 24, 2022 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-c...